Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Determining a Company’s Value - Old School

[Rumpl3StiltSkin]

CancerSlayer wrote:

CancerSlayer wrote:

Rumpl3StiltSkin wrote: Good points Fred,

I hope it is just they're focused now on NMIBC and getting us to home plate.

fredgoodwinson wrote: Rumpl - long been here for the prospective treatment of a range of cancers both by TLD-1433 and other of Sherri`s metal-based compounds which in terms of unconditional exclusivity may effectively mean Rutherrin.

There now looks to be no prospect of addressing any further cancers in this way in the foreseeable future and this is bitterly regretted - all the more so as Roswell were giving the most serious consideration to the use of TLD-1433 in lung cancer and mesothelioma.

Would TLT have the slightest difficulty in finding partners if Rutherrin has the ability to treat deep seated cancers non-invasively via low dose x-ray as repeatedly suggested in their newsletters?

Will not guess as to why after so many years`preclinical due diligence the Company so quickly rowed back from using Rutherrin in humans but with the possible exception of the present Trial you are certainly right in saying that TLT`s ACT hasn`t gone anywhere.



 

 

 

 

Agree rumpl...and an FDA approval for bcg-unresponsive NMIBC should lay a pretty solid foundation for not only future approvals, but also pave the way for the off-label use of TLD 1433 in place of Photofrin, which is currently FDA approved for multiple indications (esophageal cancer, endobronchial NSCLC & high-grade dysplasia in Barrett's esophagus = a prevalent precancerous condition).  This indication list does not include Photofrin's off-label uses (i.e. head & neck/oral cancers).  

There are multiple other globally approved photosensitizers in use that cover additional indications (I.e. skin cancer, actinic keratosis, glioma, breast cancer, etc.) that could also provide additional opportunities for use of TLD 1433.

Simply put, an approval for BCG-unresponsive NMIBC could end up being the master key that opens multiple doors...each one bigger than the next in terms of total earnings.   Good luck...

 

 

 

Recall that previous 2020 joint study (between Leiden Univ in Netherlands & Sherri's lab at UTA) that investigated the potential use of TLD 1433 as a repurposed drug.  The study demonstrated very encouraging preclinical results in the use of TLD 1433 against conjunctival melanoma cell lines (an ocular cancer).  Efficacy was tested in various cell lines, including a skin cancer cell line (melanoma).  Although the dark toxicity of TLD 1433 was noted to be low for this cell line, light activation made TLD 1433 much more potent with an EC50 value in the nanomolar range.

The moral of this story is that in addition to being a potential treatment for a rare ocular cancer, a topical form of TLD 1433 in conjunction with PDT has the potential to treat skin cancer (though not necessarily all types), which is rapidly on the rise...thanks to increasing sun exposure & commercial tanning beds.  

I am hopeful the versatility of TLD 1433 (& its derivatives) can extend beyond the scope of treating multiple indications & include a versatile range of drug formulations (i.e. a specific topical for skin vs bladder/etc., Rutherrin or other IV/systemic form for deep-seated cancers & perhaps an aerosolized form for airway infections/cancer) that can be easily scaled & better address each specific indication.

The myriad studies investigating our type of metal-based PDT all show promise.  I think our little Ph II study is "finally" beginning to shed some much overdue light on this tech's "real" potential.  All imo.

Ha Slayer, is there a commercial tanning bed franchise penny stock out there to invest in? :-)